SCHEMBL3354887

SCHEMBL3354887

Oc1cccc(-c2cncc(Br)c2)c1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 11/20 0.52
HSD17B2 P37059 9/20 0.52
CYP3A4 P08684 4/20 0.52
CYP2C9 P11712 3/20 0.52
CYP2A6 P11509 1/20 0.47
CYP11B1 P15538 4/20 0.45
CYP11B2 P19099 4/20 0.45
FYN P06241 1/20 0.45
ESR1 P03372 2/20 0.44
ESR2 Q92731 2/20 0.44
CYP1A2 P05177 2/20 0.44
CYP2D6 P10635 2/20 0.44
CYP2B6 P20813 2/20 0.44
CYP2C19 P33261 2/20 0.44
CYP17A1 P05093 1/20 0.44
CYP19A1 P11511 1/20 0.44
METAP2 P50579 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12576029 0.86 CYP2A6 (0.55) CYP2A6CYP11B1CYP11B2METAP2
SCHEMBL32670685 0.85 HSD17B1 (0.51) HSD17B1HSD17B2CYP3A4CYP2C9CYP11B1
SCHEMBL16675071 0.84 CYP2A6 (0.53) CYP2A6CYP11B1CYP11B2METAP2
SCHEMBL8207447 0.80 HSD17B1 (0.65) HSD17B1HSD17B2CYP3A4CYP2C9ESR1
SCHEMBL3346102 0.79 CYP2A6 (0.52) HSD17B1CYP2A6CYP11B1CYP11B2ESR1
SCHEMBL17460460 0.78 GABRG2 (0.55) CYP2A6CYP11B1CYP11B2CYP1A2CYP19A1
SCHEMBL5050 0.78 CYP2A6 (0.55) CYP2A6CYP11B1CYP11B2CYP19A1
SCHEMBL11992372 0.78 HSD17B1 (0.52) HSD17B1HSD17B2CYP3A4CYP2C9CYP2A6
SCHEMBL9656625 0.78 CYP2A6 (0.47) CYP2A6CYP11B1CYP11B2METAP2
SCHEMBL3372213 0.78 MEN1 (0.59) CYP3A4CYP2A6CYP11B1CYP11B2CYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2589592-B1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF FUJIFILM CORP (JP) 2018-08-22 EP disclosed
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 US disclosed
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 US disclosed
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 US disclosed
US-8809371-B2 2014-08-19 US disclosed
US-8809371-B2 2014-08-19 US disclosed
US-8809371-B2 2014-08-19 US disclosed
US-8772320-B2 2014-07-08 US disclosed
US-8772320-B2 2014-07-08 US disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 US disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 US disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 US disclosed
EP-2589592-A1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF FUJIFILM Corporation (JP) 2013-05-08 EP disclosed
EP-2589592-A1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF FUJIFILM Corporation (JP) 2013-05-08 EP disclosed
CN-102958918-A Novel nicotinamide derivatives or salts thereof FUJIFILM CORP 2013-03-06 CN disclosed
WO-2012002577-A1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF 富士フイルム株式会社 (JP) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF SYK, CD38, BTK HSD17B1 2902/4885HSD17B2 3558/4885CYP3A4 4411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.